Abstract:Bayesian adaptive designs have gained popularity in all phases of clinical trials with numerous new developments in the past few decades. During the COVID‐19 pandemic, the need to establish evidence for the effectiveness of vaccines, therapeutic treatments, and policies that could resolve or control the crisis emphasized the advantages offered by efficient and flexible clinical trial designs. In many COVID‐19 clinical trials, because of the high level of uncertainty, Bayesian adaptive designs were considered advantageous. Designing Bayesian adaptive trials, however, requires extensive simulation studies that are generally considered challenging, particularly in time‐sensitive settings such as a pandemic. In this article, we propose a set of methods for efficient estimation and uncertainty quantification for design operating characteristics of Bayesian adaptive trials. Specifically, we model the sampling distribution of Bayesian probability statements that are commonly used as the basis of decision making. To showcase the implementation and performance of the proposed approach, we use a clinical trial design with an ordinal disease‐progression scale endpoint that was popular among COVID‐19 trials. However, the proposed methodology may be applied generally in the clinical trial context where design operating characteristics cannot be obtained analytically.RésuméLes plans adaptatifs bayésiens ont gagné en popularité dans toutes les phases d'essais cliniques grâce à d'importants développements réalisés au cours des dernières décennies. Pendant la pandémie COVID‐19, la nécessité d'établir des preuves de l'efficacité des vaccins, des traitements thérapeutiques et des politiques susceptibles de résoudre ou de contrôler la crise a mis en évidence les avantages offerts par des plans d'essais cliniques efficaces et flexibles. En raison du niveau élevé d'incertitude présent dans de nombreux essais cliniques COVID‐19, les plans adaptatifs bayésiens ont été considérés comme avantageux. Cela dit, la conception d'essais adaptatifs bayésiens nécessite de vastes études de simulation qui sont généralement considérées comme difficiles, en particulier dans des contextes sensibles au facteur temps comme lors d'une pandémie. Les auteurs de cet article proposent un ensemble de méthodes d'estimation efficace et de quantification de l'incertitude pour la conception d'essais adaptatifs bayésiens. En particulier, une modélisation de la distribution d'échantillonnage des énoncés de probabilité bayésienne est proposée. Cette dernière est couramment requise lors de la prise de décisions. Pour illustrer la mise en œuvre et la performance de l'approche proposée, les auteurs ont utilisé un plan d'essai clinique avec un critère d'évaluation ordinal de l'évolution de la maladie, plan relativement populaire dans les essais COVID‐19. Aussi, la méthodologie proposée est assez générale pour être appliquée dans le contexte d'essais cliniques dont les caractéristiques opérationnelles du plan correspondant ne peuvent pas être obtenues de manière analytique.

Optimizing Interim Analysis Timing for Bayesian Adaptive Commensurate Designs

A Bayesian Group Sequential Design for Randomized Biosimilar Clinical Trials with Adaptive Information Borrowing from Historical Data

A Calibrated Power Prior Approach to Borrow Information from Historical Data with Application to Biosimilar Clinical Trials.

A Bayesian Design for Phase II Clinical Trials with Delayed Responses Based on Multiple Imputation.

An Adaptive Trial Design to Optimize Dose-Schedule Regimes with Delayed Outcomes

BASIC: A Bayesian Adaptive Synthetic-Control Design for Phase II Clinical Trials.

Bayesian Group Sequential Enrichment Designs Based on Adaptive Regression of Response and Survival Time on Baseline Biomarkers.

Improving Adaptive Seamless Designs through Bayesian optimization

Using Surrogate Endpoints in Adaptive Designs with Delayed Treatment Effect

Incorporating Historical Information to Improve Phase I Clinical Trials

Bayesian Approach for Design and Analysis of Medical Device Trials in the Era of Modern Clinical Studies

BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints

Bayesian Optimal Interval Design: A Simple and Well-Performing Design for Phase I Oncology Trials.

A Bayesian Phase II Proof-of-concept Design for Clinical Trials with Longitudinal Endpoints.

A Bayesian Response-Adaptive Covariate-Balanced Randomization Design with Application to A Leukemia Clinical Trial

Two‐stage randomized clinical trials with a right‐censored endpoint: Comparison of frequentist and Bayesian adaptive designs

On the Relative Efficiency of Model-Assisted Designs: a Conditional Approach.

New designs for Bayesian adaptive cluster-randomized trials

A Phase I-II Basket Trial Design to Optimize Dose-Schedule Regimes Based on Delayed Outcomes.

Estimating design operating characteristics in Bayesian adaptive clinical trials

A general Bayesian approach to design adaptive clinical trials with time-to-event outcomes